Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy

pharmafile | December 17, 2019 | News story | Manufacturing and Production haemophilia, haemophilia B, haemophilia a 

The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, have extended their contract for the supply of Sobi’s Elocta (efmoroctocog alfa) until 31 December 2020.

This gives another 12 months of access to Sobi’s extended half-life therapy (EHL) to those patients with haemophilia A (PwHA) requiring factor VIII (FVIII) replacement therapy in Ireland. Ireland is one of the only countries in the world to routinely offer EHL therapies as factor replacement treatment to all haemophilia patients.

This comes as a result of positive patient feedback to the HPSMAB regarding Sobi’s Elocta. St. James Hospital in Dublin, together with the HPSMAB, originally awarded Sobi the contract back in January 2018 for a minimum of two years.

The new extension to the agreement continues Sobi’s exclusive arrangement with Ireland and secures patient access to Elocta for all patients requiring factor replacement therapy.

Brian O’Mahony, Chief Executive of the Irish Haemophilia Society, said: “The availability of EHL factor concentrates has led to a measurable improvement in quality of life for people with haemophilia in Ireland.”

Neil Dugdale, Vice-President and General Manager of Sobi UK and RoI, added: “Ireland has emerged in recent years as one of the leading countries for the treatment and management of haemophilia. As part of our ongoing commitment to people living with haemophilia, we are proud to be able to continue to provide sustainable access to our EHL treatments.”

People with haemophilia A and B experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages. The World Federation of Haemophilia estimates that approximately 210,000 people are currently diagnosed with haemophilia A and B worldwide.

Conor Kavanagh

Related Content

uniQure announces sale of royalty interest in Hemgenix for up to $400m

uniQure has announced that it has entered a definitive agreement to sell a portion of …


US approval for haemophilia drug derived from genetically engineered rabbit’s milk

The FDA has announced the approval of Sevenfact, a haemophilia therapy the active ingredient from …


Novo Nordisk halts three haemophilia studies after participants suffer thrombotic events

Novo Nordisk has moved to temporarily shut down two of its Phase 3 and one …

Latest content